Search - tctmd.com

Displaying 1 - 20 of 280

Sort: Relevancy | Date

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Conference News ESC 2025

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

L.A. McKeown

September 09, 2025

News Conference News ESC 2025

DanGer Shock: Impella Tied to Better Survival Even 10 Years Later

Caitlin E. Cox

September 08, 2025

News Conference News ESC 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

Caitlin E. Cox

September 05, 2025

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

Presentation ESC 2025

Duration of Dual Antiplatelet Therapy in Acute Coronary Syndromes: The DUAL-ACS Trial

Presenter: David Newby

September 03, 2025

News Conference News ESC 2025

HELP-MI SWEDEHEART: Routine H. Pylori Screening Doesn’t Lessen Bleeding After MI

Todd Neale

September 03, 2025

Presentation ESC 2025

Randomized trial of evolocumab on saphenous vein graft patency following coronary artery bypass surgery: The NEWTON-CABG CardioLink-5 Trial

Presenter: Subodh Verma

September 01, 2025

Presentation ESC 2025

Dual or single antiplatelet therapy after coronary artery bypass grafting in patients with acute coronary syndrome: The TACSI trial

Presenter: Anders Jeppsson

September 01, 2025

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

Todd Neale

September 01, 2025

Presentation ESC 2025

Tailored Antiplatelet Therapy in High-Risk Patients Undergoing Complex PCI: The TAILORED-CHIP Randomized Clinical Trial

Presenter: Duk-Woo Park

August 31, 2025

Presentation ESC 2025

SWEDEPAD 1 and 2: Impact of drug-coated devices in patients with peripheral arterial disease

Presenter: Mårten Falkenberg, Joakim Nordanstig

August 31, 2025

Presentation ESC 2025

Helicobacter Pylori Screening after Acute Myocardial Infarction: The Cluster Randomized Crossover HELP-MI-SWEDEHEART Trial

Presenter: Robin Hofmann

August 31, 2025

News Conference News ESC 2025

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

Caitlin E. Cox

August 31, 2025

News Conference News ESC 2025

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

Michael O'Riordan

August 31, 2025

Presentation ESC 2025

PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET trial

Presenter: Pedro A. Lemos

August 30, 2025

Presentation ESC 2025

BETAMI-DANBLOCK: Randomized Discontinuation of Beta-blockers After Myocardial Infarction in Patients Without Heart Failure

Presenter: Eva Prescott, Dan Atar

August 30, 2025

Presentation ESC 2025

Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction: REBOOT

Presenter: Borja Ibanez

August 30, 2025

Presentation ESC 2025

AQUATIC: Assessment of Quitting versus Using Aspirin Therapy In patients with stabilized Coronary artery disease after stenting who require long-term oral anticoagulation

Presenter: Martine Gilard

August 30, 2025

News Conference News ESC 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Michael O'Riordan

August 30, 2025

Advertisement

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

DanGer Shock: Impella Tied to Better Survival Even 10 Years Later

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Duration of Dual Antiplatelet Therapy in Acute Coronary Syndromes: The DUAL-ACS Trial

HELP-MI SWEDEHEART: Routine H. Pylori Screening Doesn’t Lessen Bleeding After MI

Randomized trial of evolocumab on saphenous vein graft patency following coronary artery bypass surgery: The NEWTON-CABG CardioLink-5 Trial

Dual or single antiplatelet therapy after coronary artery bypass grafting in patients with acute coronary syndrome: The TACSI trial

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

Tailored Antiplatelet Therapy in High-Risk Patients Undergoing Complex PCI: The TAILORED-CHIP Randomized Clinical Trial

SWEDEPAD 1 and 2: Impact of drug-coated devices in patients with peripheral arterial disease

Helicobacter Pylori Screening after Acute Myocardial Infarction: The Cluster Randomized Crossover HELP-MI-SWEDEHEART Trial

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET trial

BETAMI-DANBLOCK: Randomized Discontinuation of Beta-blockers After Myocardial Infarction in Patients Without Heart Failure

Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction: REBOOT

AQUATIC: Assessment of Quitting versus Using Aspirin Therapy In patients with stabilized Coronary artery disease after stenting who require long-term oral anticoagulation

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content